iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) – Equities research analysts at Wedbush boosted their FY2023 earnings per share (EPS) estimates for iTeos Therapeutics in a research report issued to clients and investors on Tuesday, November 7th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($3.26) for the year, up from their previous forecast of ($3.37). Wedbush currently has a “Outperform” rating and a $33.00 target price on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.19) per share. Wedbush also issued estimates for iTeos Therapeutics’ Q4 2023 earnings at ($0.97) EPS, Q1 2024 earnings at ($1.05) EPS, Q2 2024 earnings at ($1.16) EPS, Q3 2024 earnings at ($1.30) EPS, Q4 2024 earnings at ($1.45) EPS, FY2024 earnings at ($4.96) EPS, FY2025 earnings at ($7.47) EPS, FY2026 earnings at ($0.37) EPS and FY2027 earnings at ($3.53) EPS.
Separately, HC Wainwright reduced their target price on shares of iTeos Therapeutics from $54.00 to $44.00 and set a “buy” rating on the stock in a research report on Wednesday, August 9th.
iTeos Therapeutics Stock Performance
NASDAQ:ITOS opened at $9.56 on Friday. The firm’s 50-day moving average is $10.59 and its 200-day moving average is $12.71. iTeos Therapeutics has a 52-week low of $8.20 and a 52-week high of $23.00. The company has a market cap of $342.06 million, a price-to-earnings ratio of -5.53 and a beta of 1.23.
iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.07. iTeos Therapeutics had a net margin of 9.02% and a negative return on equity of 9.72%.
Hedge Funds Weigh In On iTeos Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Hong Kong Ltd bought a new stake in shares of iTeos Therapeutics in the first quarter valued at approximately $67,000. Quadrant Capital Group LLC increased its holdings in iTeos Therapeutics by 9,041.7% in the second quarter. Quadrant Capital Group LLC now owns 2,194 shares of the company’s stock valued at $29,000 after purchasing an additional 2,170 shares during the period. Ensign Peak Advisors Inc acquired a new stake in iTeos Therapeutics in the first quarter valued at $73,000. Royal Bank of Canada grew its holdings in iTeos Therapeutics by 94.3% during the 2nd quarter. Royal Bank of Canada now owns 2,586 shares of the company’s stock worth $34,000 after acquiring an additional 1,255 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in iTeos Therapeutics during the 2nd quarter worth about $69,000. Institutional investors and hedge funds own 97.16% of the company’s stock.
Insiders Place Their Bets
In related news, CFO Matthew Gall acquired 5,000 shares of the stock in a transaction dated Thursday, October 12th. The stock was bought at an average price of $8.37 per share, with a total value of $41,850.00. Following the completion of the transaction, the chief financial officer now directly owns 19,429 shares of the company’s stock, valued at $162,620.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other iTeos Therapeutics news, CFO Matthew Gall purchased 5,000 shares of iTeos Therapeutics stock in a transaction that occurred on Thursday, October 12th. The stock was acquired at an average price of $8.37 per share, for a total transaction of $41,850.00. Following the completion of the acquisition, the chief financial officer now owns 19,429 shares of the company’s stock, valued at approximately $162,620.73. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Boxer Capital, Llc sold 350,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $16.26, for a total value of $5,691,000.00. Following the transaction, the insider now directly owns 1,804,058 shares in the company, valued at approximately $29,333,983.08. The disclosure for this sale can be found here. Company insiders own 10.20% of the company’s stock.
iTeos Therapeutics Company Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
- Five stocks we like better than iTeos Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Data giants MongoDB and Snowflake just got upgraded
- What Are Utility Stocks? An Overview of the Utilities Sector
- Plug Power at tipping point; it’s make or break time for hydrogen
- Trading Halts Explained
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.